Belgium biotech argenx has seen its income double on the back of a strong year of deals, but has also seen fit to cut two former R&D pacts.

Struggling microcap GenVec has again been warned that it will be taken off the lucrative and respected Nasdaq exchange if it doesn’t get itself out of the…

Novartis has hit the primary endpoint in what it says is the largest randomized, controlled study to date to treat secondary progressive multiple sclerosis…

Investors have plowed another $130 million into a Series B to back the startup that’s led by Genentech vets, which brings its total raised to almost $350…

In this week's EuroBiotech Report, FDA knocks Sanofi, Zealand off track, Gilead, Galapagos start Phase III program, Promethera plans IPO and more.

BioLineRx has teamed up with I-Bridge Capital to set up a Chinese drug development joint venture, iPharma.

The late-stage skin condition biotech Novan is looking to batter ongoing headwinds and gun for a $60 million public offering.

In the same week that Medivation was bought out by Pfizer in a major $14 billion deal, its former vice president of clinical development Dr. Amy Peterson has…